205 related articles for article (PubMed ID: 21353610)
1. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment.
Arfi A; Richard M; Gandolphe C; Bonnefont-Rousselot D; Thérond P; Scherman D
Mol Genet Metab; 2011 May; 103(1):18-25. PubMed ID: 21353610
[TBL] [Abstract][Full Text] [Related]
2. Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes.
Richard M; Arfi A; Rhinn H; Gandolphe C; Scherman D
J Neurosci Res; 2008 Nov; 86(15):3285-94. PubMed ID: 18646207
[TBL] [Abstract][Full Text] [Related]
3. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
[TBL] [Abstract][Full Text] [Related]
4. Brain Targeting in MPS-IIIA.
Sorrentino NC; Fraldi A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA.
Roberts AL; Thomas BJ; Wilkinson AS; Fletcher JM; Byers S
Pediatr Res; 2006 Sep; 60(3):309-14. PubMed ID: 16857766
[TBL] [Abstract][Full Text] [Related]
6. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.
Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S
Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
Gliddon BL; Hopwood JJ
Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
[TBL] [Abstract][Full Text] [Related]
8. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
Hemsley KM; King B; Hopwood JJ
Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
[TBL] [Abstract][Full Text] [Related]
9. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
Savas PS; Hemsley KM; Hopwood JJ
Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
[TBL] [Abstract][Full Text] [Related]
10. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
[TBL] [Abstract][Full Text] [Related]
11. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
[TBL] [Abstract][Full Text] [Related]
12. Innate and adaptive immune activation in the brain of MPS IIIB mouse model.
DiRosario J; Divers E; Wang C; Etter J; Charrier A; Jukkola P; Auer H; Best V; Newsom DL; McCarty DM; Fu H
J Neurosci Res; 2009 Mar; 87(4):978-90. PubMed ID: 18951493
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
[TBL] [Abstract][Full Text] [Related]
14. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).
Hemsley KM; Hopwood JJ
Behav Brain Res; 2005 Mar; 158(2):191-9. PubMed ID: 15698885
[TBL] [Abstract][Full Text] [Related]
15. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress is independent of inflammation in the neurodegenerative Sanfilippo syndrome type B.
Trudel S; Trécherel E; Gomila C; Peltier M; Aubignat M; Gubler B; Morlière P; Heard JM; Ausseil J
J Neurosci Res; 2015 Mar; 93(3):424-32. PubMed ID: 25332157
[TBL] [Abstract][Full Text] [Related]
17. Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain.
Robinson AJ; Zhao G; Rathjen J; Rathjen PD; Hutchinson RG; Eyre HJ; Hemsley KM; Hopwood JJ
Cell Transplant; 2010; 19(8):985-98. PubMed ID: 20350350
[TBL] [Abstract][Full Text] [Related]
18. Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells.
Keating DJ; Winter MA; Hemsley KM; Mackenzie KD; Teo EH; Hopwood JJ; Brooks DA; Parkinson-Lawrence EJ
Neuroscience; 2012 Dec; 227():110-8. PubMed ID: 23022219
[TBL] [Abstract][Full Text] [Related]
19. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice.
Lau AA; Crawley AC; Hopwood JJ; Hemsley KM
Behav Brain Res; 2008 Aug; 191(1):130-6. PubMed ID: 18453006
[TBL] [Abstract][Full Text] [Related]
20. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
